Which of the following is NOT a recommended measure in Duchenne muscular dystrophy management?

Which of the following is NOT a recommended measure in Duchenne muscular dystrophy management?

• A. Routine intense weight-bearing exercise without supervision
• B. Vitamin D and calcium supplementation
• C. Adrenal crisis awareness
• D. Regular growth monitoring

Answer: (D)

The management of Duchenne usually aims to slow progression, preserve function, and prevent complications. Avoiding routine intense weight-bearing exercise without supervision is important because fragile, dystrophic muscles can be more easily injured, and excessive activity can worsen weakness and damage. Vitamin D and calcium supplementation helps protect bone health, which is particularly important given steroid use and reduced mobility that raise fracture risk. Adrenal crisis awareness is essential because many patients receive chronic corticosteroids; illness or stress can precipitate adrenal insufficiency, so recognizing and responding to signs early is crucial. Regular growth monitoring, while important for overall pediatric care and for tracking effects of therapies, is not a direct therapeutic intervention for Duchenne itself and does not modify disease progression, which is why it’s the choice that isn’t considered a targeted management measure.

The management of Duchenne usually aims to slow progression, preserve function, and prevent complications. Avoiding routine intense weight-bearing exercise without supervision is important because fragile, dystrophic muscles can be more easily injured, and excessive activity can worsen weakness and damage. Vitamin D and calcium supplementation helps protect bone health, which is particularly important given steroid use and reduced mobility that raise fracture risk. Adrenal crisis awareness is essential because many patients receive chronic corticosteroids; illness or stress can precipitate adrenal insufficiency, so recognizing and responding to signs early is crucial. Regular growth monitoring, while important for overall pediatric care and for tracking effects of therapies, is not a direct therapeutic intervention for Duchenne itself and does not modify disease progression, which is why it’s the choice that isn’t considered a targeted management measure.